サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1417743

GLP-1受容体作動薬市場レポート：2030年までの動向、予測、競合分析

Glucagon-Like Peptide 1 Agonists Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 - page report | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

GLP-1受容体作動薬市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

GLP-1受容体作動薬の動向と予測

GLP-1受容体作動薬の世界市場は、2024年から2030年までのCAGRが6.0%で、2030年までに推定251億米ドルに達すると予測されます。この市場の主な促進要因は、2型糖尿病、肥満および関連疾患の症例の増加、不健康なライフスタイルへの適応の増加、糖尿病疾患の遺伝歴、および高齢化人口の増加です。GLP-1受容体作動薬の世界市場の将来は、病院と専門クリニックの市場における機会によって有望視されています。

GLP-1受容体作動薬市場の洞察

Lucintel社は、肥満率の増加、2型糖尿病の遺伝的リスク因子の増加により、デュラグルチドが予測期間中最大のセグメントであり続けると予測しています。

北米は、研究開発の拡大やヘルスケア施設の増加により、予測期間中も最大地域であり続けるでしょう。

よくある質問

Q1.市場規模は？

A1.GLP-1受容体作動薬の世界市場は、2030年までに推定251億米ドルに達すると予想されています。

Q2.市場の成長予測は？

A2.GLP-1受容体作動薬の世界市場は、2024年から2030年にかけてCAGR 6.0％で成長すると予測されます。

Q3.市場の成長に影響を与える主な促進要因は？

A3.この市場の主な促進要因は、2型糖尿病、肥満および関連疾患の症例の増加、不健康なライフスタイルへの適応の増加、糖尿病疾患の遺伝歴、および高齢化人口の増加です。

Q4.市場の主要セグメントは？

A4.GLP-1受容体作動薬の世界市場の将来は、病院と専門クリニックの市場機会が有望です。

Q5.市場の主要企業は？

A5.GLP-1受容体作動薬の主要企業は以下の通りです。

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Q6.今後、最大となる市場セグメントは？

A6.Lucintel社は、肥満率の増加、2型糖尿病の遺伝的危険因子の増加により、デュラグルチドが予測期間中最大のセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は？

A7.北米は、研究開発の拡大とヘルスケア施設の増加により、予測期間中も最大地域であり続ける。

Q8.レポートのカスタマイズは可能？

A8.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のGLP-1受容体作動薬市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のGLP-1受容体作動薬市場動向（2018～2023年）および予測（2024～2030年）
  • 薬物の種類別の世界のGLP-1受容体作動薬市場
    • エクセナチド
    • リラグルチド
    • リキシセナチド
    • デュラグルチド
  • ブランド別の世界のGLP-1受容体作動薬市場
    • バイエッタ
    • ビデュリオン
    • ビクトーザ
    • トルリシティ
    • リクスミア
  • 投与経路別の世界のGLP-1受容体作動薬市場
    • 経口
    • 非経口
    • その他
  • 最終用途別の世界のGLP-1受容体作動薬市場
    • 病院
    • 専門クリニック
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のGLP-1受容体作動薬市場
  • 北米のGLP-1受容体作動薬市場
  • 欧州のGLP-1受容体作動薬市場
  • アジア太平洋のGLP-1受容体作動薬市場
  • その他地域のGLP-1受容体作動薬市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 薬物の種類別の世界のGLP-1受容体作動薬市場の成長機会
    • ブランド別の世界のGLP-1受容体作動薬市場の成長機会
    • 投与経路別の世界のGLP-1受容体作動薬市場の成長機会
    • 最終用途別の世界のGLP-1受容体作動薬市場の成長機会
    • 地域別の世界のGLP-1受容体作動薬市場の成長機会
  • 世界のGLP-1受容体作動薬市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のGLP-1受容体作動薬市場の能力拡大
    • 世界のGLP-1受容体作動薬市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan
目次

Glucagon-Like Peptide 1 Agonists Trends and Forecast

The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets. The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

A more than 150-page report is developed to help in your business decisions.

Glucagon-Like Peptide 1 Agonists by Segment

The study includes a forecast for the global glucagon-like peptide 1 agonists by drug type, brand, route of administration, end use, and region.

Glucagon-Like Peptide 1 Agonists Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Exenatide
  • Liraglutide
  • Lixisenatide
  • Dulaglutide

Glucagon-Like Peptide 1 Agonists Market by Brand [Shipment Analysis by Value from 2018 to 2030]:

  • Byetta
  • Bydureon
  • Victoza
  • Trulicity
  • Lyxumia

Glucagon-Like Peptide 1 Agonists Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral
  • Others

Glucagon-Like Peptide 1 Agonists Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Others

Glucagon-Like Peptide 1 Agonists Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Glucagon-Like Peptide 1 Agonists Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glucagon-like peptide 1 agonists companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glucagon-like peptide 1 agonists companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Glucagon-Like Peptide 1 Agonists Market Insights

Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Features of the Global Glucagon-Like Peptide 1 Agonists Market

Market Size Estimates: Glucagon-like peptide 1 agonists market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glucagon-like peptide 1 agonists market size by various segments, such as by drug type, brand, route of administration, end use, and region in terms of value ($B).

Regional Analysis: Glucagon-like peptide 1 agonists market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, brand, route of administration, end use, and regions for the glucagon-like peptide 1 agonists market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glucagon-like peptide 1 agonists market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the glucagon-like peptide 1 agonists market size?

Answer: The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030.

Q2. What is the growth forecast for glucagon-like peptide 1 agonists market?

Answer: The global glucagon-like peptide 1 agonists market is expected to grow with a CAGR of 6.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glucagon-like peptide 1 agonists market?

Answer: The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

Q4. What are the major segments for glucagon-like peptide 1 agonists market?

Answer: The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets.

Q5. Who are the key glucagon-like peptide 1 agonists market companies?

Answer: Some of the key glucagon-like peptide 1 agonists companies are as follows.

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Q6. Which glucagon-like peptide 1 agonists market segment will be the largest in future?

Answer: Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

Q7. In glucagon-like peptide 1 agonists market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the glucagon-like peptide 1 agonists market by drug type (exenatide, liraglutide, lixisenatide, and dulaglutide), brand (byetta, bydureon, victoza, trulicity, and lyxumia), route of administration (oral, parenteral, and others), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Glucagon-Like Peptide 1 Agonists Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Glucagon-Like Peptide 1 Agonists Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
    • 3.3.1: Exenatide
    • 3.3.2: Liraglutide
    • 3.3.3: Lixisenatide
    • 3.3.4: Dulaglutide
  • 3.4: Global Glucagon-Like Peptide 1 Agonists Market by Brand
    • 3.4.1: Byetta
    • 3.4.2: Bydureon
    • 3.4.3: Victoza
    • 3.4.4: Trulicity
    • 3.4.5: Lyxumia
  • 3.5: Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
    • 3.5.1: Oral
    • 3.5.2: Parenteral
    • 3.5.3: Others
  • 3.6: Global Glucagon-Like Peptide 1 Agonists Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Glucagon-Like Peptide 1 Agonists Market by Region
  • 4.2: North American Glucagon-Like Peptide 1 Agonists Market
    • 4.2.2: North American Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.3: European Glucagon-Like Peptide 1 Agonists Market
    • 4.3.1: European Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.3.2: European Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.4: APAC Glucagon-Like Peptide 1 Agonists Market
    • 4.4.1: APAC Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.4.2: APAC Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.5: ROW Glucagon-Like Peptide 1 Agonists Market
    • 4.5.1: ROW Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.5.2: ROW Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Brand
    • 6.1.3: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
    • 6.1.4: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by End Use
    • 6.1.5: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Region
  • 6.2: Emerging Trends in the Global Glucagon-Like Peptide 1 Agonists Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Glucagon-Like Peptide 1 Agonists Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glucagon-Like Peptide 1 Agonists Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Bristol-Myers Squibb Company
  • 7.3: AstraZeneca
  • 7.4: Pfizer
  • 7.5: Baxter
  • 7.6: Hikma Pharmaceuticals
  • 7.7: Amneal Pharmaceuticals
  • 7.8: Teva Pharmaceuticals
  • 7.9: Sun Pharmaceuticals
  • 7.10: Mylan